Proactive Investors - Run By Investors For Investors

Motif Bio receives vote of confidence as it raises £2.7mln

Chief executive Graham Lumsden said: "We are encouraged by the support shown by both new and existing investors as we strengthen our balance sheet"
Motif Bio receives vote of confidence as it raises £2.7mln
Motif has developed an antibiotic to tackle acute skin infections

Motif Bio PLC (LON:MTFB, NASDAQ:MTFB) received a monetary boost – and by extension a vote of confidence in its prospects – as it raised £2.7mln via a share placing.

The cash will fund the business through the coming months as it meets with officials at the US Food & Drug Administration (FDA) to discuss the future of its antibiotic, iclaprim.

The treatment, which was developed to tackle acute bacterial skin infections, was knocked by the FDA last month.

The watchdog wants additional data so it can “further evaluate the risk for liver toxicity” before it decides whether or not to grant new drug approval. As one of Motif’s advisers pointed out, this wasn’t a straight ‘no’. So there may still be some hope.

Of course, Motif is keen “to discuss potential options to address the deficiencies” with the information it had furnished. But ahead of the fundraiser, there had been real concerns the business might run out of cash.

Meeting scheduled

A meeting with the FDA is scheduled for May 3, and the company expects a response a month later.

Proceeds from the placing, which was completed at 6p a share, will provide a financial runway long enough to see it past the date it receives the minutes from the regulator in June.

Chief executive Graham Lumsden said: "We are encouraged by the support shown by both new and existing investors as we strengthen our balance sheet.

“The company now expects to be funded through completion of the FDA meeting and receipt of the minutes, which should provide guidance regarding the path forward for iclaprim."

View full MTFB profile View Profile

Motif Bio PLC Timeline

Newswire
May 07 2019

Related Articles

word cancer under magnifying glass
May 01 2019
The oncology-focused biotech is a mid-clinical-stage therapeutics company.
blood samples in test tubes
October 25 2018
The NYSE-listed company has designed a routine blood test to screen for colorectal and prostate cancers that reduces the need for more invasive colonoscopies and biopsies
test tubes
April 16 2019
Summit Therapeutics' potential breakthrough targets C.difficile

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use